卡马西平抗体

鼠抗卡马西平抗体

产品简介：

鼠抗卡马西平单克隆抗体，Carbamazepine antibody

Carbamazepine was first discovered and developed in Basel, Switzerland, at the labs of J.R. Geigy AG by Schindler and others around 1954. Initially, it was recognized as a treatment for trigeminal neuralgia (Blom 1962). The anticonvulsant properties of carbamazepine were subsequently reported in animals (Theobald and Kunz 1963) and clinical trials in humans (Lustig 1964) in the early 1960s. Since then, numerous trials have demonstrated carbamazepine to be effective in the treatment of partial onset and generalized seizures. Carbamazepine was originally introduced in Switzerland and the UK in 1963 as an antiepileptic medication. In the USA, carbamazepine won initial approval by the FDA for treatment of trigeminal neuralgia in 1968. Approval for use in epilepsy (Tegretol) did not occur until 1974, and was not extended to use in children until several decades later.

其它名称：卡马西平抗体，鼠抗CBZ抗体，Carbamazepine antibody

货号：grCB101

应用：CLIA

特异性：Carbamazepine

来源：Mouse

存贮：-20℃

产品说明：

卡马西平是一种抗癫痫药物，化学上与三环类抗抑郁药有关。卡马西平现在被批准作为双相情感障碍的二线治疗，在治疗急性躁狂发作方面有很好的证据。卡马西平对治疗酒精和苯二氮卓类戒断综合征也有效

Carbamazepine  was approved as a mood stabilizer in 2004 and has also been shown to be beneficial for psychosis in Alzheimer dementia.3,4Carbamazepine acts primarily as an antiepileptic by blocking voltage gated sodium channels and L-type calcium channels.It also demonstrates antagonism of the anti-NMDA receptor (like valproic acid) but to a lesser extent.

Thought to have mood stabilization properties because of its close structural relationship to imipramine, carbamazepine has been comparable to lithium and haloperidol for mood stabilization in several large trials. The literature also has shown carbamazepine’s utilization for acute agitation.

产品注意事项：

1.本品为蛋白质制剂，未添加任何防腐剂和保护剂，在2-8℃可以短暂保存。

2.本品仅作为诊断试剂原辅材料，不得用于诊断或治疗。